Trial
NCT02289144
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Novartis
Condition
Metastatic Anaplastic Thyroid Cancer
Intervention
Ceritinib
Why stopped
study was on hold for protocol redesign; decided to not move forward with study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-30